Nocebo in headache

Current Opinion in Neurology

Volumn 29, Issue 3, 2016, Pages 331-336

  Mitsikostas, Dimos D ^a  

^a ATHENS NAVAL HOSPITAL   (Greece)

Author keywords

adherence; adverse events; headache; nocebo; treatment outcome

Indexed keywords

BOTULINUM TOXIN A; PLACEBO; TRIPTAN DERIVATIVE;

ANOREXIA; CLUSTER HEADACHE; FIBROMYALGIA; HEADACHE; HUMAN; META ANALYSIS (TOPIC); MIGRAINE; MULTIPLE SCLEROSIS; NAUSEA; NOCEBO EFFECT; PARKINSON DISEASE; PHONOPHOBIA; PHOTOPHOBIA; PLACEBO EFFECT; PRIMARY HEADACHE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW (TOPIC); TENSION HEADACHE; TREATMENT OUTCOME;

HEADACHE; HUMANS; MIGRAINE DISORDERS; NOCEBO EFFECT; TREATMENT OUTCOME;

EID: 84959232797     PISSN: 13507540     EISSN: 14736551     Source Type: Journal    
DOI: 10.1097/WCO.0000000000000313     Document Type: Review

References (37)

1. Steiner TJ, Birbeck GL, Jensen RH, et al. Headache disorders are third cause of disability worldwide. J Headache Pain 2015; 16:58.
2. Steiner TJ, Stovner LJ, Katsarava Z, et al. The impact of headache in Europe: principal results of the Eurolight project. J Headache Pain 2014; 15:31.
3. Rozen TD, Fishman RS. Cluster headache in the United States of America: demographics, clinical characteristics, triggers, suicidality, and personal burden. Headache 2012; 52:99-113.
4. Gracia-Naya M, Santos-Lasaosa S, Ŕios-Gómez C, et al. Predisposing factors affecting drop-out rates in preventive treatment in a series of patients with migraine. Rev Neurol 2011; 53:201-208.
5. Mitsikostas DD, Mantonakis LI, Chalarakis NG. Nocebo is the enemy, not placebo. A meta-analysis of reported side effects after placebo treatment in headaches. Cephalalgia 2011; 31:550-561.
6. Luykx J, Mason M, Ferrari MD, Carpay J. Are migraineurs at increased risk of adverse drug responses? A meta-analytic comparison of topiramate-related adverse drug reactions in epilepsy and migraine. Clin Pharmacol Ther 2009; 85:283-288.
7. Mitsikostas DD. Nocebo in headaches: implications for clinical practice and trial design. Curr Neurol Neurosci Rep 2012; 12:132-137.
8. Hepp Z, Dodick DW, Varon SF, et al. Adherence to oral migraine-preventive medications among patients with chronic migraine. Cephalalgia 2015; 35:478-488.
9. Kennedy WP. The nocebo reaction. Med World 1961; 95:203-205.
10. Barsky AJ, Saintfort R, Rogers MP, et al. Nonspecific medication side effects and the nocebo phenomenon. JAMA 2002; 287:622-627.
11. Ellingsen D-M, Wessberg J, Eikemo M, et al. Placebo improves pleasure and pain through opposite modulation of sensory processing. Proc Natl Acad Sci USA 2013; 110:17993-17998.
12. Enck P, Benedetti F, Schedlowski M. New insights into the placebo and nocebo responces. Neuron 2008; 59:195-206.
13. Scott DJ, Stohler CS, Egnatuk CM, et al. Placebo and nocebo effects are defined by opposite opioid and dopaminergic responses. Arch Gen Psychiatry 2008; 65:220-231.
14. Benedetti F, Lanotte M, Lopiano L, et al. When words are painful: unraveling the mechanisms of the nocebo effect. Neuroscience 2007; 147:260-271.
15. Benedetti F, Durando J, Vighetti S. Nocebo and placebo modulation of hypobaric hypoxia headache involves the cyclooxygenase-prostaglandins pathway. Pain 2014; 155:921-928.
16. Benedetti F, Durando J, Giudetti L, et al. High-altitude headache: the effects of real vs. sham oxygen administration. Pain 2015; 156:2326-2336.
17. Frisaldi E, Piedimonte A, Benedetti F. Placebo and nocebo effects: a complex interplay between psychological factors and neurochemical networks. Am J Clin Hypn 2015; 57:267-284.
18. Evans WR. Headaches and the nocebo effect. Headache 2003; 43:1111-1115.
19. Cohen S. The nocebo effect of informed consent. Bioethics 2014; 28:147-154.
20. Heller MK, Chapman SC, Horne R. Beliefs about medication predict the misattribution of a common symptom as a medication side effect: evidence from an analogue online study. J Psychosom Res 2015; 79:519-529.
21. Colloca L, Miller FG. The nocebo effect and its relevance for clinical practice. Psychosom Med 2011; 73:598-603.
22. Reuter U, Sanchez del Rio M, Carpay JA, et al. GSK headache masters program: placebo adverse events in headache trials: headache as an adverse event of placebo. Cephalalgia 2003; 23:496-503.
23. Loder E, Goldstein R, Biondi D. Placebo effects in oral triptan trials: the scientific and ethical rationale for continued use of placebo controls. Cepha-lalgia 2005; 25:124-131.
24. Amanzion M, Corazzini LL, Vase L, Benedetti F. A systematic review of adverse events in placebo groups of antimigraine clinical trials. Pain 2009; 146:261-269.
25. Dodick DW, Turkel CC, DeGryse RE, et al. Onabotulinumtoxin A for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache 2010; 50:921-936.
26. Silberstein SD, Dodick DW, Aurora SK, et al. Per cent of patients with chronic migraine who responded per onabotulinumtoxinA treatment cycle: PREEMPT. J Neurol Neurosurg Psychiatry 2015; 86:996-1001.
27. Allena M, Steiner TJ, Sances G, et al. Impact of headache disorders in Italy and the public-health and policy implications: a population-based study within the Eurolight Project. J Headache Pain 2015; 16:100.
28. Stathis P, Smpiliris M, Konitsiotis S, Mitsikostas DD. Nocebo as a potential confounding factor in clinical trials for Parkinson's disease treatment: a meta-analysis. Eur J Neurol 2013; 20:527-533.
29. Mitsikostas DD, Chalarakis NG, Mantonakis LI, et al. Nocebo in fibromyalgia: meta-analysis of placebo-controlled clinical trials and implications for practice. Eur J Neurol 2012; 19:672-680.
30. Papadopoulos D, Mitsikostas DD. Nocebo effects in multiple sclerosis trials: a meta-analysis. Mult Scler 2010; 16:816-828.
31. Zis P, Mitsikostas DD. Nocebo in Alzheimer's disease; meta-analysis of placebo-controlled clinical trials. J Neurol Sci 2015; 355:94-100.
32. Mitsikostas DD, Mantonakis L, Chalarakis N. Nocebo in clinical trials for depression: a meta-analysis. Psychiatry Res 2014; 215:82-86.
33. Papadopoulos D, Mitsikostas DD. A meta-analytic approach to estimating nocebo effects in neuropathic pain trials. J Neurol 2012; 259:436-447.
34. Mitsikostas DD, Deligianni CI. Q-No: a questionnaire to predict nocebo in outpatients seeking neurological consultation. Neurol Sci 2015; 36:379-381.
35. Benedetti F, Amanzio M. The placebo response: how words and rituals change the patient's brain. Patient Educ Couns 2011; 84:413-419.
36. Colloca L, Finniss D. Nocebo effects, patient-clinician communication, and therapeutic outcomes. JAMA 2012; 307:567-568.
37. Greville-Harris M, Dieppe P. Bad is more powerful than good: the nocebo response in medical consultations. Am J Med 2015; 128:126-129.